Plus Therapeutics, Inc.
PSTV
$0.7691
-$0.075-8.89%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 18.54% | 52.63% | 113.20% | 733.42% | 2,093.30% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 18.54% | 52.63% | 113.20% | 733.42% | 2,093.30% |
| Cost of Revenue | 9.18% | 23.84% | 14.09% | -13.10% | -0.09% |
| Gross Profit | 0.44% | -3.41% | 23.01% | 66.70% | 49.58% |
| SG&A Expenses | 16.33% | -5.76% | -11.88% | -17.69% | -16.54% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.53% | 8.47% | 0.78% | -15.33% | -8.54% |
| Operating Income | -10.31% | 2.54% | 16.43% | 41.98% | 32.42% |
| Income Before Tax | 2.54% | 15.03% | 22.92% | 43.85% | 34.32% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 2.54% | 15.03% | 22.92% | 43.85% | 34.32% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.54% | 15.03% | 22.92% | 43.85% | 34.32% |
| EBIT | -10.31% | 2.54% | 16.43% | 41.98% | 32.42% |
| EBITDA | -10.08% | 2.92% | 17.07% | 43.29% | 33.52% |
| EPS Basic | 54.09% | 60.86% | 62.03% | 71.01% | 61.83% |
| Normalized Basic EPS | 54.09% | 60.86% | 62.02% | 71.01% | 61.83% |
| EPS Diluted | 48.29% | 56.63% | 58.79% | 71.00% | 61.81% |
| Normalized Diluted EPS | 58.05% | 63.75% | 64.25% | 71.01% | 61.83% |
| Average Basic Shares Outstanding | 111.43% | 125.06% | 108.34% | 84.79% | 79.58% |
| Average Diluted Shares Outstanding | 145.22% | 166.25% | 155.99% | 84.79% | 79.58% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |